Howe et al. demonstrated that combining erlotinib with different FAK inhibitors impacted cell viability in vitro and reduced tumor growth in vivo to a higher degree than single-agent treatment, correlating with reduced Akt phosphorylation [37]. This evidence concerns the gene PTK2 and neoplasm.